SAN DIEGO — In early cuts of data, the next iteration of KRAS drugs for lung cancer appears to bear more promise than the first. KRAS mutations drive around a quarter of all cancer cases and …
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
